Extended Data Fig. 1: Correspondence of CSF measures with amyloid PET status, tau PET status, or clinical status. | Nature Aging

Extended Data Fig. 1: Correspondence of CSF measures with amyloid PET status, tau PET status, or clinical status.

From: CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease

Extended Data Fig. 1: Correspondence of CSF measures with amyloid PET status, tau PET status, or clinical status.The alternative text for this image may have been generated using AI.

Correspondence of the CSF measures with amyloid PET status was evaluated in the amyloid PET cohort (n = 750 individuals) (A), and correspondence with tau PET status was evaluated in tau PET cohort (n = 371 individuals) (B). Correspondence of the CSF measures with clinical status (cognitively normal [CDR = 0] or cognitively impaired [CDR > 0]) was evaluated in the larger amyloid PET cohort (n = 750 individuals) (C). Lines represent the receiver operating characteristic area under the curve point estimate (middle point) and 95% confidence intervals. Black lines represent correspondence in the entire cohort and the red lines represent correspondence in amyloid PET positive individuals.

Back to article page